GSK’s Arexvy Cuts RSV Hospitalizations by 75.6%, Reduces Cardiovascular Risks
In a US study of over 2.5 million adults aged 60+, GSK’s Arexvy vaccine demonstrated 75.6% effectiveness against RSV-related hospitalizations and 63.1% fewer cardiovascular events. It also cut COPD flare-ups by 74.4% and asthma exacerbations by 61.6%, and a Danish cohort saw 100% hospitalization prevention.
1. Study Highlights
GSK conducted a large-scale US real-world analysis involving more than 2.5 million adults aged 60 and older, finding that a single dose of Arexvy achieved 75.6% effectiveness against RSV-related hospital admissions compared with unvaccinated peers.
2. Cardiovascular and Respiratory Benefits
Beyond hospitalization reduction, vaccinated individuals experienced a 63.1% drop in major cardiovascular events during RSV-related stays. The data also showed a 74.4% decrease in severe COPD flare-ups and a 61.6% reduction in asthma exacerbations among those with underlying respiratory conditions.
3. Danish Cohort Results
A parallel nationwide study in Denmark reported 100% prevention of RSV-related hospitalizations in a subgroup of COPD patients aged 60 and over, underscoring Arexvy’s potential for high-risk populations and bolstering its real-world effectiveness profile.